ATE516277T1 - Carbonsäureverbindungen und arzneimittel, die diese verbindungen als wirkstoffe enthalten - Google Patents
Carbonsäureverbindungen und arzneimittel, die diese verbindungen als wirkstoffe enthaltenInfo
- Publication number
- ATE516277T1 ATE516277T1 AT03710260T AT03710260T ATE516277T1 AT E516277 T1 ATE516277 T1 AT E516277T1 AT 03710260 T AT03710260 T AT 03710260T AT 03710260 T AT03710260 T AT 03710260T AT E516277 T1 ATE516277 T1 AT E516277T1
- Authority
- AT
- Austria
- Prior art keywords
- diseases
- formula
- accompanied
- compounds
- carboxylic acid
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- -1 CARBOXYLIC ACID COMPOUNDS Chemical class 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 3
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 208000003251 Pruritus Diseases 0.000 abstract 2
- 208000024780 Urticaria Diseases 0.000 abstract 2
- 201000008937 atopic dermatitis Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract 1
- 206010006482 Bronchospasm Diseases 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 208000004262 Food Hypersensitivity Diseases 0.000 abstract 1
- 206010016946 Food allergy Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 206010038848 Retinal detachment Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 201000008736 Systemic mastocytosis Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 230000036783 anaphylactic response Effects 0.000 abstract 1
- 208000003455 anaphylaxis Diseases 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000024998 atopic conjunctivitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 238000010009 beating Methods 0.000 abstract 1
- 230000007885 bronchoconstriction Effects 0.000 abstract 1
- 230000020411 cell activation Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 235000020932 food allergy Nutrition 0.000 abstract 1
- 210000003630 histaminocyte Anatomy 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 208000008423 pleurisy Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000004264 retinal detachment Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 238000006748 scratching Methods 0.000 abstract 1
- 230000002393 scratching effect Effects 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/06—Six-membered rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Otolaryngology (AREA)
- Toxicology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002076456 | 2002-03-19 | ||
| PCT/JP2003/002635 WO2003078409A1 (en) | 2002-03-19 | 2003-03-06 | Carboxyoic acid compounds and drugs containing the compounds as the active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE516277T1 true ATE516277T1 (de) | 2011-07-15 |
Family
ID=28035445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03710260T ATE516277T1 (de) | 2002-03-19 | 2003-03-06 | Carbonsäureverbindungen und arzneimittel, die diese verbindungen als wirkstoffe enthalten |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7351705B2 (de) |
| EP (1) | EP1486491B1 (de) |
| JP (2) | JP4547913B2 (de) |
| KR (1) | KR20040095302A (de) |
| CN (1) | CN100378083C (de) |
| AT (1) | ATE516277T1 (de) |
| AU (1) | AU2003221325A1 (de) |
| BR (1) | BR0308518A (de) |
| CA (1) | CA2479352A1 (de) |
| ES (1) | ES2365985T3 (de) |
| IL (1) | IL164094A0 (de) |
| MX (1) | MXPA04009095A (de) |
| NO (1) | NO20043894L (de) |
| NZ (1) | NZ535309A (de) |
| PL (1) | PL372466A1 (de) |
| RU (1) | RU2329256C2 (de) |
| WO (1) | WO2003078409A1 (de) |
| ZA (1) | ZA200407461B (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003297398B2 (en) | 2002-12-20 | 2009-09-24 | Amgen Inc. | Asthma and allergic inflammation modulators |
| AR041089A1 (es) | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
| DK1666473T3 (da) * | 2003-09-17 | 2013-03-25 | Ono Pharmaceutical Co | Carboxylsyreforbindelser og medicinske sammensætninger indeholdende samme som aktiv ingrediens |
| PE20050483A1 (es) | 2003-10-31 | 2005-08-25 | Arena Pharm Inc | Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas |
| US20070244107A1 (en) * | 2004-08-25 | 2007-10-18 | Waters M Gerard | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions |
| CA2586156A1 (en) * | 2004-11-04 | 2006-05-18 | Merck & Co., Inc. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| WO2006052798A2 (en) * | 2004-11-08 | 2006-05-18 | Merck & Co., Inc. | Method of treating pathological blushing |
| US20070281969A1 (en) * | 2004-11-23 | 2007-12-06 | Colletti Steven L | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment |
| PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
| WO2006068162A1 (ja) * | 2004-12-24 | 2006-06-29 | Shionogi & Co., Ltd. | 慢性閉塞性肺疾患の治療剤 |
| US20080139604A1 (en) * | 2005-02-17 | 2008-06-12 | Shaun Fitzpatrick | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions |
| KR101289995B1 (ko) | 2005-09-27 | 2013-07-26 | 시오노기 앤드 컴파니, 리미티드 | Pgd2 수용체 길항제 활성을 갖는 설폰아마이드 유도체 |
| EP2037967B1 (de) | 2006-06-16 | 2016-12-07 | The Trustees Of The University Of Pennsylvania | Prostaglandin d2 rezeptor antagonisten zur behandlung androgener alopezie |
| EP2114154B1 (de) * | 2007-02-08 | 2013-08-28 | Merck Sharp & Dohme Corp. | Verfahren zur behandlung von atherosklerose, hyperlipidämien und verwandten erkrankungen |
| TWI410410B (zh) * | 2007-08-10 | 2013-10-01 | Ono Pharmaceutical Co | Phenylacetic acid compounds |
| GB0721611D0 (en) * | 2007-11-02 | 2007-12-12 | Glaxo Group Ltd | Novel compounds |
| ES2471919T3 (es) | 2007-12-19 | 2014-06-27 | Amgen, Inc | Derivados de ácido fenilac�tico como moduladores de inflamación |
| WO2010030360A1 (en) | 2008-09-11 | 2010-03-18 | Arena Pharmaceuticals, Inc. | 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS |
| PH12012500676A1 (en) * | 2009-10-08 | 2015-06-03 | Sanofi Sa | Phenyloxadiazole derivatives as pgds inhibitors |
| ES2991300T3 (es) | 2015-02-13 | 2024-12-03 | Inserm Institut Nat De La Sante Et De Larecherche Medicale | Antagonistas de PTGDR-1 y/o PTGDR-2 para prevenir y/o tratar lupus eritematoso sistémico |
| IL310383A (en) * | 2018-09-20 | 2024-03-01 | Ono Pharmaceutical Co | DP antagonist |
| WO2020218316A1 (ja) * | 2019-04-26 | 2020-10-29 | 日産化学株式会社 | アリールスルホン酸エステル化合物の製造方法 |
| JP7047954B2 (ja) * | 2020-03-19 | 2022-04-05 | 小野薬品工業株式会社 | フェニル酢酸化合物を含有する医薬組成物 |
| TW202146394A (zh) * | 2020-03-19 | 2021-12-16 | 日商小野藥品工業股份有限公司 | 苯乙酸化合物之結晶 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4994479A (en) * | 1985-04-03 | 1991-02-19 | Yamanouchi Pharmaceutical Co., Ltd. | Phenylene derivatives and anti-allergic use thereof |
| IE911919A1 (en) * | 1990-06-21 | 1992-01-01 | Zeneca Ltd | Bicyclic heterocyclic compounds |
| NZ336143A (en) | 1996-12-13 | 2002-05-31 | Shionogi & Co | Benzothiophenecarboxamide derivatives and pgd 2 antagonists comprising them |
| MXPA02008801A (es) * | 2000-03-09 | 2003-07-07 | Ono Pharmaceutical Co | Derivados de indol, proceso para la preparacion de los mismos y su uso. |
-
2003
- 2003-03-06 MX MXPA04009095A patent/MXPA04009095A/es active IP Right Grant
- 2003-03-06 US US10/507,885 patent/US7351705B2/en not_active Expired - Fee Related
- 2003-03-06 BR BR0308518-0A patent/BR0308518A/pt not_active IP Right Cessation
- 2003-03-06 ES ES03710260T patent/ES2365985T3/es not_active Expired - Lifetime
- 2003-03-06 IL IL16409403A patent/IL164094A0/xx unknown
- 2003-03-06 JP JP2003576415A patent/JP4547913B2/ja not_active Expired - Fee Related
- 2003-03-06 AU AU2003221325A patent/AU2003221325A1/en not_active Abandoned
- 2003-03-06 CN CNB03811495XA patent/CN100378083C/zh not_active Expired - Fee Related
- 2003-03-06 NZ NZ535309A patent/NZ535309A/en unknown
- 2003-03-06 PL PL03372466A patent/PL372466A1/xx not_active Application Discontinuation
- 2003-03-06 WO PCT/JP2003/002635 patent/WO2003078409A1/ja not_active Ceased
- 2003-03-06 CA CA002479352A patent/CA2479352A1/en not_active Abandoned
- 2003-03-06 EP EP03710260A patent/EP1486491B1/de not_active Expired - Lifetime
- 2003-03-06 RU RU2004130837/04A patent/RU2329256C2/ru not_active IP Right Cessation
- 2003-03-06 AT AT03710260T patent/ATE516277T1/de not_active IP Right Cessation
- 2003-03-06 KR KR10-2004-7014688A patent/KR20040095302A/ko not_active Ceased
-
2004
- 2004-09-16 ZA ZA200407461A patent/ZA200407461B/en unknown
- 2004-09-17 NO NO20043894A patent/NO20043894L/no not_active Application Discontinuation
-
2010
- 2010-04-30 JP JP2010105565A patent/JP5168315B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP5168315B2 (ja) | 2013-03-21 |
| IL164094A0 (en) | 2005-12-18 |
| CN100378083C (zh) | 2008-04-02 |
| JPWO2003078409A1 (ja) | 2005-07-14 |
| ZA200407461B (en) | 2005-07-01 |
| PL372466A1 (en) | 2005-07-25 |
| EP1486491A4 (de) | 2006-02-15 |
| JP4547913B2 (ja) | 2010-09-22 |
| BR0308518A (pt) | 2005-02-22 |
| WO2003078409A1 (en) | 2003-09-25 |
| CA2479352A1 (en) | 2003-09-25 |
| US7351705B2 (en) | 2008-04-01 |
| EP1486491A1 (de) | 2004-12-15 |
| JP2010189431A (ja) | 2010-09-02 |
| AU2003221325A1 (en) | 2003-09-29 |
| RU2004130837A (ru) | 2005-05-27 |
| KR20040095302A (ko) | 2004-11-12 |
| NZ535309A (en) | 2006-05-26 |
| ES2365985T3 (es) | 2011-10-14 |
| NO20043894L (no) | 2004-12-17 |
| EP1486491B1 (de) | 2011-07-13 |
| RU2329256C2 (ru) | 2008-07-20 |
| MXPA04009095A (es) | 2004-12-06 |
| US20050222216A1 (en) | 2005-10-06 |
| CN1656085A (zh) | 2005-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE516277T1 (de) | Carbonsäureverbindungen und arzneimittel, die diese verbindungen als wirkstoffe enthalten | |
| WO2006044732A3 (en) | 2, 6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists | |
| JP7221021B2 (ja) | 毒性アルデヒド関連疾患および処置 | |
| TNSN07251A1 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| MX2008011369A (es) | Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2. | |
| TNSN08515A1 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| TNSN08131A1 (en) | Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist | |
| ES2396913T3 (es) | Compuestos moduladores de sirtuina | |
| NO20054878L (no) | 2-Fenoksy- og 2-fenylsulfonamidderivater med CCR3-antagonistisk aktivitet for behandling av astma og andre inflammasjons- eller immunologiske forstyrrelser | |
| WO2005021515A3 (en) | Inhibitors of phosphodiesterase type-iv | |
| AU2006218403A1 (en) | Fused heterocyclic compounds and their use as sirtuin modulators | |
| ATE354572T1 (de) | Substituierte 1-piperidin-4-yl-4-azetidin-3-yl- piperazinderivate und deren verwendung als neurokininantagonisten | |
| CN101277963A (zh) | 作为sirtuin调节剂的噁唑并吡啶衍生物 | |
| WO2005051931A3 (en) | Phosphodiesterase inhibitors | |
| BRPI0414487A (pt) | composto de ácido carboxìlico e composições medicinais contendo os mesmos como o ingrediente ativo | |
| WO2006085212A3 (en) | Condensed isoxaline derivatives as inhibitors of phosphodiesterase type-iv | |
| Chen et al. | Design, synthesis and antithrombotic evaluation of novel non-peptide thrombin inhibitors | |
| UA95303C2 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
| UA90319C2 (ru) | Соединения 2,6-хинолинила и их применение как лекарственного средства | |
| TH84867A (th) | สารประกอบเฮทเทอโรไซคลิคใหม่ที่เป็นประโยชน์สำหรับการรักษาความผิดปกติทางการอักเสบและทางด้านภูมิแพ้ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |